oral semaglutide approval Drug Watch: The version of is now approved for weight reduction, with a maintenance dose of 25 mg daily. "For patients paying for the oral option out of pocket, the Novo Nordisk's Wegovy® pill (oral

GLP-1 Is considered to be an incretin hormone, which means that it works to promote the production of insulinan important benefit for those who wish to support a healthy blood glucose response

In Canada, Wegovy is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or greater (obesity), or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea

Schedule a visit with a licensed health care provider and discuss your health history, goals, and whether you meet prescribing criteria for a GLP-1 medicine

Weeks 5 to 8 (0.5 mg, 10 units at 5 mg/mL): Appetite suppression becomes more noticeable

Weight Loss Results Differ : Clinical trials show Wegovy patients achieve approximately 15-18% weight loss over 68 weeks, while Ozempic results in 8-14% weight loss when used at diabetes treatment doses

In management's eyes, like we've just been talking about, there's so much consolidation happening in the industry